SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Algorand (ALGO) is a cryptocurrency launched in 2019. Algorand has a current supply of 10,000,000,000 with 9,078,194,480.417637 in circulation. The last known price of Algorand is 0.09693394 USD and is up 3.39 over the last 24 hours. It is currently trading on 586 active market(s) with $57,858,585.39 traded over the last 24 hours. More information can be found at http://algorand.foundation.

Algorand

ALGOs weak price action near key resistance and its prolonged decline are driving a technical debate: bearish traders see limited momentum and risk of further losses, while bulls call the pullbacks accumulation ahead of a possible altcoin recovery. Some bullish discussion also points to the new leadership and Algorands quantum-security and tokenization themes, though these are presented as longer-term prospects.

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.

Astrazeneca plc

AstraZeneca PLC

AstraZenecas reported, non-binding offer for Rhythm Pharmaceuticals is drawing attention, with traders debating whether a deal will proceed and whether other bidders may emerge. The proposal also fuels discussion about AZNs strategy in rare and obesity treatments, though some traders question the fit and point to other potential pipeline targets.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshires latest quarterly results are driving attention: operating earnings softened, particularly in insurance, while share repurchases surged to a quarterly record. Traders view the buybacks as a sign management sees value in the shares, while others focus on the weaker insurance performance and question whether Berkshire is deploying its capital effectively.

Alcoa Corp. engages in the bauxite mining, alumina refining, and aluminum smelting and casting. It operates through the Alumina and Aluminum segments. The Alumina segment consists of a refining system, including the mining of bauxite, which is then refined into alumina, a compound of aluminum and oxygen that is the raw material used by smelters to produce aluminum metal. The Aluminum segment is composed of smelting and casthouse system. The company was founded by Charles Martin Hall on July 9, 1886 and is headquartered in Pittsburgh, PA.

Alcoa Corp

Alcoas mixed Q3 results are driving discussion: traders point to the earnings and cash-flow strength, while others focus on the revenue miss, weaker operating trends, and cost pressures. The debate also reflects concern about aluminums cyclical outlook and the South32 acquisition, with some investors seeing long-term upside and others expecting further downside.

Atlassian Corp. is a holding company, which engages in providing team collaboration and productivity software. Its products include Jira Software, Confluence, Jira Service Management, and Loom. The company was founded by Michael Cannon-Brookes and Scott Farquhar in October 2002 and is headquartered in San Francisco, CA.

Atlassian Corporation - Ordinary Shares - Class A

Atlassian Corporation Plc

Atlassians earnings beat was followed by a sharp selloff as traders focused on a slower growth outlook and declining Data Center guidance rather than the backward-looking results. Some see the drop as an overreaction, while others worry that AI adoption and cautious hiring could pressure cloud growth and per-seat demand.

Invesco Exchange-Traded Fund Trust - Invesco S&P 500 Equal Weight ETF

Invesco S&P 500 Equal Weight ETF

Rotation away from mega-cap technology and into the broader S&P 500 has put RSPs equal-weight breadth signal in focus. Traders view its relative strength and record highs as evidence of wider participation, while skeptics warn that weakening breadth or a reversal in RSP could signal broader market trouble.

Lam Research Corp. engages in the design, manufacture, marketing, refurbishment, and provision of semiconductor processing equipment used in the fabrication of integrated circuits. It operates through the following geographical segments: United States, China, Europe, Japan, Korea, Southeast Asia, and Taiwan. The company was founded by David K. Lam in 1980 and is headquartered in Fremont, CA.

Lam Research Corp.

Lam Researchs large new share-repurchase authorization is driving a sharp rebound after a steep selloff, with bullish traders viewing it as a signal of management confidence and potential support for shares. Others remain cautious because the prior earnings reaction centered on supply constraints, a modest outlook and weaker expected China revenue, and some question whether the bounce will last.

NextDecade Corp. is a development company, which focuses on liquefied natural gas (LNG) export projects and associated pipelines. It develops and manages land-based and floating liquefied natural gas projects in the Gulf Coast with focus on the Rio Grande LNG. The company was founded by Kathleen Eishbrenner in 2010 and is headquartered in Houston, TX.

NextDecade Corporation

Geopolitical disruption to Middle Eastern LNG supplies, especially concerns around Qatar and Strait of Hormuz shipping, has traders watching NextDecade as a potential beneficiary of stronger demand for U.S. exports. The bullish view is tempered by skepticism that the company can capitalize before Rio Grande LNG begins production, with construction, financing and execution risks still central to the debate.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Attention centers on Candels planned BLA filing for CAN-2409 in localized prostate cancer, with recent SITC immune-profiling and viral-shedding data drawing interest as potential support for the regulatory package. Bulls see the Phase 3 results and filing timeline as meaningful catalysts, while skeptics question the datas completeness, managements transparency, and the risk of delay or dilution.

Select Sector SPDR Trust (The) - State Street Health Care Select Sector SPDR ETF

Health Care Select Sector SPDR Fund

Healthcares strong relative performance is drawing attention as traders describe capital rotating into defensive sectors and away from technology and semiconductors. The community is split between bullish views that the rally can continue and concerns about profit-taking or a reversal, with options activity also showing bets on both directions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ETFs That You May Consider Amid a Strengthening Biotech Outlook

Drug innovation, AI and rising M&A activity are boosting biotech optimism. Discover ETFs offering exposure to the sector.

Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate 

Biotech ETFs offer diversified exposure to oncology innovation as cancer funding surges and the global oncology drug market expands.

Should You Invest in the VanEck Biotech ETF (BBH)?

The Zacks Analyst Blog Highlights Amgen, Crinetics, FBT, BBH and BBP

Biotech ETFs are riding innovation, obesity drug growth and M&A, offering diversified exposure to the sector???s powerful rally.

Bet on These Biotech ETFs as Innovation Drives Market-Beating Growth 

 Biotech ETFs are riding a powerful rally fueled by innovation, obesity drugs and M&A, with three funds offering diversified exposure to growth.

Healthcare ETFs Are Looking Up: Here's Why 

Healthcare ETFs are hitting 52-week highs as earnings improve, dealmaking accelerates, FDA approvals stay strong and investors seek defensive growth.

Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market

GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.

GILD Stock Jumps After Winning Accelerated FDA Approval For HDV Treatment 

Equity

 U.S. Food and Drug Administration (FDA) approved Hepcludex (bulevirtide-gmod) injection to treat chronic hepatitis delta virus.

VanEck ETF Trust - VanEck Biotech ETF

Bearish Sentiment

<ul class="summary-bullets"><li>Chronic HDV is considered the most severe form of viral hepatitis.</li><li>Bulevirtide 2 mg is also approved for use in the European Economic Area (EEA).&nbsp;</li><li>Gilead Sciences concluded the acquisition of Germany -based biotech firm Tubulis.</li></ul>Gilead Sciences (<a href="https://stocktwits.com/symbol/GILD">GILD</a>) share price gained nearly 3% on Friday and was set to record its best day in about three months after Federal regulators granted accelerated approval to Hepcludex, making it the first and only approved treatment in the U.S. for adults with chronic hepatitis delta virus infection.&nbsp;Chronic hepatitis delta, or HDV, only occurs as a co-infection in individuals who already carry the hepatitis B virus. It is associated with rapid progression to liver disease, liver failure, liver cancer and death. Health officials estimate that the disease affects between 40,000 and 80,000 Americans."Today's approval fills a critical gap in care for patients with chronic HDV infection, who until now have had no FDA-approved therapies available," said Dr. Wendy Carter, acting director of the Office of Infectious Diseases in the FDA’s Center for Drug Evaluation and Research.Hepcludex, known chemically as bulevirtide-gmod, acts as a first-in-class entry inhibitor, blocking both HDV and hepatitis B from entering liver cells and disrupting the viral lifecycle. It is administered via a once-daily injection for adults who either do not have cirrhosis or have compensated cirrhosis, a state where the liver is scarred but still functional.&nbsp;"The approval of Hepcludex represents a historic milestone for people living with HDV in the United States," said Dr. Dietmar Berger, chief medical officer at Gilead Sciences in a statement. "This reflects years of close engagement with the FDA and the application of rigorous science to address a serious disease with long-standing unmet need."&nbsp;In the U.S., HDV affects between 2% and 4% of individuals who have chronic hepatitis B virus (HBV), representing ~40,000-80,000 people, Gilead said in a release citing studies.&nbsp;<h2 class="st-heading-2">MYR301 study&nbsp;</h2>The FDA’s decision was heavily informed by data from a multi-center Phase 3 clinical trial, known as MYR301.Participants were randomly assigned to immediate treatment with Hepcludex 8.5 mg once daily for 144 weeks or to delayed treatment with an observational period of 48 weeks followed by Hepcludex 8.5 mg once daily for 96 weeks.Furthermore, data showed that the percentage of participants with completely undetectable viral levels climbed steadily from 20% at week 48 to 50% by week 144.The FDA previously granted Hepcludex breakthrough therapy and orphan-drug designations to expedite its review. While newly approved in the U.S., a 2 mg dose of the drug has already been available in the European Economic Area and other global markets.&nbsp;<h2 class="st-heading-2">GILD Retail View&nbsp;</h2>Retail sentiment on Stocktwits was ‘normal’ with ‘high’ message volumes.&nbsp;The stock has gained 29% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Gilead Sciences logo is displayed on a smartphone screen, with the company's branding visible in the background, on April 20, 2025, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

Gilead Sciences (GILD) share price gained nearly 3% on Friday and was set to record its best day in about three months after Federal regulators granted accelerated approval to Hepcludex, making it the first and only approved treatment in the U.S. for adul

VanEck Biotech ETF

Gilead Sciences, Inc.

iShares Biotechnology ETF

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$253.47
Prev Close	$251.01
Open	$247.48
Dividend Yield	N/A
50-Day Moving Average	$242.35
Beta	N/A
Avg. Volume	13,213.19
PE Ratio	N/A

52-Week High	$263.74
52-Week Low	$179.25
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

BBH Fundamentals